Results 61 to 70 of about 2,521,326 (308)

Predicting value of HE4 and CA125 markers for optimal cytoreductive surgery in ovarian cancer patients

European Journal of Translational Myology, 2022
We conducted a cross-sectional study to evaluate the role of serum levels of CA125 and HE4 in predicting optimal cytoreductive surgery. Eligible women who had been diagnosed with ovarian cancer based on both clinical and imaging criteria were enrolled ...
Elham Saffarieh, Setare Nassiri, Majid Mirmohammadkhani   +2 more
doaj   +1 more source

Carcinoembryonic antigen‐specific, fluorescent image‐guided cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer

British Journal of Surgery, 2020
This multicentre pilot study investigated the role of peroperative carcinoembryonic antigen (CEA)‐specific fluorescence imaging during cytoreductive surgery–hyperthermic intraperitoneal chemotherapy surgery in peritoneal metastasized colorectal cancer. A
D. Schaap, K. S. de Valk, M. Deken, R. Meijer, J. Burggraaf, A. Vahrmeijer, M. Kusters   +6 more
semanticscholar   +1 more source

Treatment options for PNET liver metastases. a systematic review [PDF]

, 2018
Pancreatic neuroendocrine tumors (PNETs) are rare pancreatic neoplasms. About 40-80% of patients with PNET are metastatic at presentation, usually involving the liver (40-93%). Liver metastasis represents the most significant prognostic factor.
Aurello, Paolo, Crovetto, Anna, Debs, Tarek, Mangogna, Livia Maria, Moschetta, Giovanni, Nigri, Giuseppe, Persechino, Raffaello, Petrucciani, Niccolò, Ramacciato, Giovanni   +8 more
core   +1 more source

Treatment of PERItoneal disease in Stomach Cancer with cytOreductive surgery and hyperthermic intraPEritoneal chemotherapy: PERISCOPE I initial results

British Journal of Surgery, 2020
The role of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer is unknown. This non‐randomized dose‐finding phase I–II study was designed to assess the safety and feasibility of HIPEC, following ...
R. T. van der Kaaij, E. Wassenaar, W. Koemans, K. Sikorska, C. Grootscholten, M. Los, A. Huitema, J. Schellens, A. Veenhof, K. Hartemink, A. Aalbers, B. van Ramshorst, D. Boerma, H. Boot, J. V. van Sandick   +14 more
semanticscholar   +1 more source

Preclinical evaluation of local prolonged release of paclitaxel from gelatin microspheres for the prevention of recurrence of peritoneal carcinomatosis in advanced ovarian cancer [PDF]

, 2019
Patients with advanced ovarian cancer develop recurrence despite initial treatment response to standard treatment of surgery and intravenous/intraperitoneal (IP) chemotherapy, partly due to a limited peritoneal exposure time of chemotherapeutics ...
Ceelen, Wim, De Clercq, Kaat, De Wever, Olivier, Descamps, Benedicte, Hoorens, Anne, Vermeulen, An, Vervaet, Chris, Xie, Feifan   +7 more
core   +2 more sources

The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma

, 2021
Pseudomyxoma Peritonei (PMP) and Peritoneal Mesothelioma (PM) are both rare peritoneal malignancies. Currently, affected patients may be treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy offering long-term survival or even ...
Ceelen, Wim, de Hingh, IHJT, Deraco, M, Glehen, O, Govaerts, K, Kepenekian, V, Kusamura, S, Lurvink, RJ, Moran, BJ, of PSOGI collaborators, List, Van der Speeten, K, Villeneuve, L   +11 more
core   +1 more source

Intraperitoneal photodynamic therapy causes a capillary-leak syndrome. [PDF]

, 2003
BackgroundIn patients undergoing intraperitoneal (IP) photodynamic therapy (PDT), the combination of aggressive surgical debulking and light therapy causes an apparent systemic capillary-leak syndrome that necessitates significant intensive care unit ...
Canter, Robert J, Fraker, Douglas L, Glatstein, Eli J, Hahn, Stephen M, Kesmodel, Susan B, Metz, James M, Mick, Rosemarie, Raz, Dan J, Spitz, Francis R   +8 more
core   +2 more sources

Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis.

Journal of Clinical Oncology, 2019
PURPOSE Gastric cancer (GC) with peritoneal metastases (PMs) is a poor prognostic evolution. Cytoreductive surgery (CRS) yields promising results, but the impact of hyperthermic intraperitoneal chemotherapy (HIPEC) remains controversial. Here we aimed to
P. Bonnot, G. Piessen, V. Kepenekian, E. Decullier, M. Pocard, B. Meunier, J. Bereder, K. Abboud, F. Marchal, F. Quénet, D. Goéré, S. Msika, C. Arvieux, N. Pirró, R. Wernert, P. Rat, J. Gagnière, J. Lefèvre, T. Courvoisier, R. Kianmanesh, D. Vaudoyer, M. Rivoire, P. Meeus, G. Passot, O. Glehen   +24 more
semanticscholar   +1 more source

Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis : mission possible? [PDF]

, 2017
A
Ceelen, Wim, Dakwar, George, De Smedt, Stefaan, Remaut, Katrien, Shariati, Molood, Willaert, Wouter   +5 more
core   +2 more sources

The acceleration of metastases after tumor removal and the paradoxical phenomenon of concomitant tumor resistance [PDF]

, 2018
Although surgical extirpation of tumors is usually clinically recommended, tumor removal may entail an undesired side effect: the risk of accelerating the growth of metastases.
Chiarella, Paula, Meiss, Roberto P., Montagna, Daniela Romina, Ruggiero, Raul Alejandro   +3 more
core   +1 more source